Pauline K Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5254219/publications.pdf

Version: 2024-02-01

686830 794141 22 933 13 19 citations h-index g-index papers 23 23 23 1723 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The effect of timing of initiation of renal replacement therapy on mortality: A retrospective case–control study. Journal of the Intensive Care Society, 2021, 22, 8-16.	1.1	O
2	Predicting Intensive Care Transfers and Other Unforeseen Events: Analytic Model Validation Study and Comparison to Existing Methods. JMIR Medical Informatics, 2021, 9, e25066.	1.3	20
3	Variation in Early Management Practices inÂModerate-to-Severe ARDS in the UnitedÂStates. Chest, 2021, 160, 1304-1315.	0.4	38
4	Utilization of Intensive Care Unit Nutrition Consultation Is Associated With Reduced Mortality. Journal of Parenteral and Enteral Nutrition, 2020, 44, 213-219.	1.3	3
5	An Unusual Cause of Severe Hypoxemia and Acute Respiratory Distress Syndrome. Chest, 2020, 158, e71-e77.	0.4	1
6	Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock*. Critical Care Medicine, 2020, 48, 1445-1453.	0.4	41
7	Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. Annals of the American Thoracic Society, 2020, 17, 1144-1153.	1.5	24
8	Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Medicine, 2019, 45, 1360-1371.	3.9	117
9	AAST Critical Care Committee clinical consensus: ECMO, nutritionExtracorporeal membrane oxygenation (ECMO)Nutrition. Trauma Surgery and Acute Care Open, 2019, 4, e000304.	0.8	17
10	Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*. Critical Care Medicine, 2019, 47, 632-642.	0.4	149
11	Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2019, 7, 317-324.	0.9	137
12	Computed Tomography Evidence of Psoas Muscle Atrophy Without Concomitant Tendon Wasting in Early Sepsis. Journal of Surgical Research, 2019, 234, 210-216.	0.8	9
13	Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Medicine, 2018, 44, 717-729.	3.9	230
14	Early Goal-Directed Therapy: The History and Ongoing Impact on Management of Severe Sepsis and Septic Shock. Surgical Infections, 2018, 19, 142-146.	0.7	7
15	Extracorporeal Membrane Oxygenation Support Following Stem Cell Transplant—When Is All That We Have Still Not Enough?*. Critical Care Medicine, 2017, 45, 925-926.	0.4	8
16	Extracorporeal Life Support. Critical Care Medicine, 2017, 45, 2106-2107.	0.4	0
17	Incidence, risk factors, and mortality associated with acute respiratory distress syndrome in combat casualty care. Journal of Trauma and Acute Care Surgery, 2016, 81, S150-S156.	1.1	25
18	The Prevention of Organ Failure: The PROOF Will Be in the Pudding. Annals of the American Thoracic Society, 2016, 13, 777-778.	1.5	3

#	Article	IF	CITATIONS
19	Reduction in Venous Thromboembolism Events: Trauma Performance Improvement and Loop Closure Through Participation in a State-Wide Quality Collaborative. Journal of the American College of Surgeons, 2015, 221, 661-668.	0.2	27
20	Characteristics and Outcomes of Patients Hospitalized Following Pulmonary Aspiration. Chest, 2014, 146, 899-907.	0.4	31
21	Transfusion strategies and development of acute respiratory distress syndrome in combat casualty care. Journal of Trauma and Acute Care Surgery, 2013, 75, S238-S246.	1.1	45
22	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infectious Diseases, 0, , .	0.4	1